Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 48, Issue 2, 2009, Pages 176-185

  Donnelly, Craig ^a   Bangs, Mark ^b   Trzepacz, Paula ^b   Jin, Ling ^b   Zhang, Shuyu ^b   Witte, Michael M ^b   Ball, Susan G ^b   Spencer, Thomas J ^c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Safety; Tolerability

Indexed keywords

ATOMOXETINE;

ABDOMINAL PAIN; ACNE; AGED; AGGRESSION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATTENTION DEFICIT DISORDER; BILIRUBIN BLOOD LEVEL; BRONCHITIS; CHILD; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COUGHING; DECREASED APPETITE; DEPRESSED MOOD; DEPRESSION; DIABETIC KETOACIDOSIS; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; EAR INFECTION; EPISTAXIS; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; FEVER; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART MURMUR; HOSTILITY; HUMAN; HYPERTENSION; INFLUENZA; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; NOSE CONGESTION; OPPOSITIONAL DEFIANT DISORDER; OTITIS MEDIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULSE RATE; QT PROLONGATION; RASH; RHINOPHARYNGITIS; SEASONAL ALLERGY; SEDATION; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SORE THROAT; STOMACH DISCOMFORT; STREPTOCOCCAL PHARYNGITIS; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TACHYCARDIA; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; VIRUS INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; WOLFF PARKINSON WHITE SYNDROME;

EID: 60449113063     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1097/CHI.0b013e318193060e     Document Type: Article

References (35)

1. Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699-711.
2. Jensen PS, Arnold LE, Swanson JM et al. 3-Year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry. 2007;46: 989-1002.
3. Wilens TE, Biederman J, Spencer TJ, Prince J. Pharmacotherapy of adult attention deficit/hyperactivity disorder: a review. J Clin Psychopharmacol. 1995;15:270-279.
4. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;1081033-1044.
5. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry. 1999;56:1073-1086.
6. Michelson D, Buitelaar JK, Danckaerts M et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43:896-904.
7. Kelsey DK, Sumner CR, Casat CD et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics. 2004;114:e1-e8.
8. Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002;159: 1896-1901.
9. Michelson D, Faries D, Wernicke J et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001; 108:e83.
10. Spencer T, Heiligenstein JH, Biederman J et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactiviry disorder. J Clin Psychiatry. 2002;63: 1140-1147.
11. Kratochvil CJ, Heiligenstein JH, Dittmann R et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002;41: 776-784.
12. Wilens TE, Newcorn JH, Kratochvil CJ et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr. 2006;149:112-119.
13. Kratochvil CJ, Wilens TE, Greenhill LL et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperaccivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45: 919-927.
14. Spencer TJ, Kratochvil CJ, Sangal RB et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol. 2007; 17:689-700.
15. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry. 2002;63(suppl 12):50-55.
16. Kratochvil C, Newcorn J, Arnold E et al. Atomoxetine alone or combined with fluoxetine for treating ADHD comorbid with depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44:915-924.
17. Allen AJ, Kurlan RM, Gilbert DL et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65:1941-1949.
18. Weiss M, Tannock R, Kratochvil C et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2005;44: 647-655.
19. Newcorn J, Kratochvil C, Allen AJ et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165:721-730.
20. Sangal RB, Owens J, Allen AJ et al. Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep. 2006;29:1573-1585.
21. Spencer T, Biederman J, Heiligenstein J et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11:251-265.
22. Trzepacz PT, Williams DW, Feldman PD, Wrishko RE, Witcher JW, Buitelaar JK. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol. 2008;18:79-86.
23. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
24. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46:242-251.
25. Committee for Proprietary Medicinal Products. The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products. London: The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit; 1997.
26. Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics. 2005;116:e74-e80.
27. Swanson JM, Elliott GR, Greenhill LL et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46:1015-1027.
28. Current Diagnosis and Treatment in Pediatrics. 18th ed. New York: McGraw-Hill; 2007. Table 19-5.
29. Wernicke JF, Paries D, Girod D et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26:729-740.
30. Prasad S, Purr AJ, Zhang S, Ball S, Allen AJ. Baseline values from the electrocardiograms of children and adolescents with ADHD. Child Adolesc Psychiatry Ment Health. 2007;1:11.
31. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731-739.
32. Atomoxetine hydrochloride. In: US Full Prescribing Information. Indianapolis: Eli Lilly and Co; 2007, pp. 1-7.
33. Bangs ME, Tauscher-Wisniewski S, Polzer J et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry. 2008;47(2):209-218.
34. Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics. 1998;8:529-541.
35. Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther. 1999;65:570-575.